Betamethasone, calcipotriol (Dovobet, Xamiol)
Betamethasone, calcipotriol
Adcock ingram limited
Registration
- Applicant
- Adcock ingram limited
- Certificate holder
- Adcock ingram limited
- Registrations
- 3
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dovobet EACH 1,0 g OINTMENT CONTAINS :BETAMETHASONE DIPROPIONATE EQUIVALENT TO BETAMETHASONE 0,5 mg, CALCIPOTRIOL 50,0 ug | 50 μgOintment. | 37024137/13.9.1/0241Approved 28 July 2023 | Registered | Not determined | PIPIL |
| Xamiol gel EACH 1,0 g GEL CONTAINS BETAMETHASONE DIPROPIONATE EQUIVALENT TO BETAMETHASONE 0,5 mg, CALCIPOTRIOL 50,0 ug | Gel | 44063244/13.9.1/0632 | Cancelled | Not determined | None |
| Dovobet gel EACH 1,0 g GEL CONTAINS: BETAMETHASONE DIPROPIONATE EQUIVALENT TO BETAMETHASONE 0,5 mg, CALCIPOTRIOL 50,0 ug | Gel | 46061546/13.9.1/0615 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Betamethasone
Consolidated Schedules 06 July 2026, line 5481
S3: Calcipotriol
Consolidated Schedules 06 July 2026, line 3258
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.